Paper Details

  1. Home
  2. Paper Details

Randomized Phase II Trial of Bevacizumab or Temsirolimus in Combination With Chemotherapy for First Relapse Rhabdomyosarcoma: A Report From the Children's Oncology Group.

Author: AndersonJames R, ChiYueh-Yun, DasguptaRoshni, HawkinsDouglas S, HingoraniPooja, IndelicatoDaniel J, KaoSimon C, LydenElizabeth R, MascarenhasLeo, MeyerWilliam H, RodebergDavid A, SpuntSheri L

Clinical Trial, Phase IIA Phase II trial is a trial that further evaluates the efficacy and safety of a new drug or treatment, whose safety has been confirmed to some extent in a Phase I trial, in a small number of patients.
Comparative StudyResearch that compares multiple groups/interventions to determine differences/similarities in outcomes/characteristics.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Multicenter StudyResearch conducted in collaboration with multiple research institutions. It aims to collect a wide range of data and obtain more generalizable results.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, N.I.H., ExtramuralResearch funding provided by the NIH to external research institutions and researchers.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

Temsirolimus showed a superior event-free survival compared to bevacizumab in patients with rhabdomyosarcoma (RMS) in first relapse.
Paper Details　
Original Abstract of the Article :
PURPOSE: The primary aim of this clinical trial was to prioritize bevacizumab or temsirolimus for additional investigation in rhabdomyosarcoma (RMS) when administered in combination with cytotoxic chemotherapy to patients with RMS in first relapse with unfavorable prognosis. PATIENTS AND METHODS: P...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6823886/

データ提供：米国国立医学図書館（NLM）

Prioritizing Treatment Options for Relapsed Rhabdomyosarcoma

This research embarks on a journey through the challenging landscape of cancer treatment, focusing on rhabdomyosarcoma, a rare but aggressive type of cancer that often affects children. It's like navigating a treacherous desert, seeking the most effective path to combat a formidable enemy. The study examines the potential of two targeted therapies, bevacizumab and temsirolimus, in combination with chemotherapy for patients with relapsed rhabdomyosarcoma. It's like exploring different strategies to overcome a sandstorm, seeking the most effective way to protect the caravan and its precious cargo.

Finding the Most Effective Approach

The study found that temsirolimus, when combined with chemotherapy, yielded a superior event-free survival rate compared to bevacizumab. It's like discovering a more powerful weapon in the fight against cancer, offering a greater chance of success against this formidable foe. The researchers concluded that temsirolimus holds promise as a potential treatment option for relapsed rhabdomyosarcoma, encouraging further investigation into this targeted therapy. It's a reminder that relentless research and innovation are essential in the battle against cancer, providing hope for better outcomes and a brighter future.

Hope on the Horizon

This study offers a ray of hope, like a distant oasis appearing on the horizon, for patients with relapsed rhabdomyosarcoma. It suggests that temsirolimus, when combined with chemotherapy, could offer a more effective treatment option, improving survival rates and potentially extending lives. It's a testament to the power of research and the unwavering pursuit of new and innovative treatments, offering a glimmer of hope for those facing the challenges of cancer.

Dr.Camel's Conclusion

This research highlights the importance of continued research and the development of targeted therapies in the fight against cancer. It's a reminder that the journey of medicine is a relentless quest for better treatments and improved outcomes for those affected by this devastating disease.
Date :
  1. Date Completed 2020-06-15
  2. Date Revised 2020-11-01
Further Info :

Pubmed ID

31513481

DOI: Digital Object Identifier

PMC6823886

Related Literature

Article Analysis
・Effects of temsirolimus
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.